Therapeutic value of atorvastatin combined bezafibrate on adjusting lipid therapy in patients with acute coronary syndrome
10.3969/j.issn.1008-0074.2015.06.15
- VernacularTitle:阿托伐他汀联合苯扎贝特对急性冠脉综合征患者的疗效
- Author:
Yong ZHAO
;
Xianxia LIU
- Publication Type:Journal Article
- Keywords:
Acute coronary syndrome;
Bezafibrate;
Atorvastatin
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2015;24(6):637-640
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the therapeutic value of atorvastatin combined bezafibrate on adjusting lipid in pa‐tients with acute coronary syndrome (ACS) .Methods :A total of 121 ACS patients who were treated in our hospital from Apr 2013 to Sep 2013 were enrolled .According to therapeutic method ,they were divided into bezafibrate group (n=60 ,received bezafibrate treatment based on routine treatment ) and combined treatment group (n=61 , received additional atorvastatin based on treatment of bezafibrate group ) .Levels of total cholesterol (TC) ,triglyc‐eride (TG) ,low density lipoprotein cholesterol (LDL‐C) and high density lipoprotein cholesterol (HDL‐C) ,stand‐ard‐reaching rate of blood lipid and incidence rate of adverse reactions were compared between two groups before and after treatment .Results:Before treatment ,there were no significant difference in all blood lipid levels between two groups , P> 0.05. Compared with before treatment ,levels of TC ,TG and LDL‐C significantly reduced and HDL‐C level significantly rose in both groups after treatment , P< 0.05 or < 0.01 ;Compared with bezafibrate group ,there were significant reductions in levels of TC [ (4.06 ± 0.49) mmol/L vs .(3.35 ± 0.29) mmol/L] ,TG [ (1.60 ± 0.33) mmol/L vs .(1.12 ± 0.21) mmol/L] and LDL‐C [ (2.18 ± 0.39) mmol/L vs .(1.91 ± 0.26) mmol/L] ,and significant rise in HDL‐C level [ (1.09 ± 0.21) mmol/L vs .(1.26 ± 0.26) mmol/L] ,P<0.05 all;and sig‐nificant rise in standard‐reaching rates of TC (41.67% vs .67.21% ) ,TG (61.67% vs .85.25% ) ,LDL‐C (36.67%vs .70.49% ) and HDL‐C (41.67% vs .90.16% ) in combined treatment group after treatment ,P<0.05 all .There was no significant difference in incidence rate of adverse reactions (11.48% vs .10.00% ) between combined treat‐ment group and bezafibrate group , P>0.05. Conclusion:Atorvastatin combined bezafibrate can significantly im‐prove blood lipid condition and possess good safety in ACS patients .
